September 1, 2020 News by Joana Carvalho, PhD SomaCeuticals Acquires Rights to Formula Targeting Lesions in MS SomaCeuticals, a subsidiary of AngioSoma, has acquired exclusive global rights to a patented formula that aims to ease and possibly eliminate signs of neurodegeneration in people with multiple sclerosis (MS). By entering a licensing agreement with 7 to Stand, a Delaware corporation, SomaCeuticals gained access…
July 26, 2017 News by Alice Melão, MSc Wealthy Oilman with Multiple Sclerosis Funds Canadian Studies for Promising MS Therapy Canadian oilman Hank Swartout made a fortune as longtime founder and CEO of Precision Drilling. The Calgary native mortgaged his house to start the company, which by the time he left in 2009 had annual sales of $7 billion. But an early diagnosis of multiple sclerosis (MS) at the age…
June 6, 2017 Columns by Ed Tobias Jumping to Conclusions About a MS Treatment Those of us with multiple sclerosis are always on the alert for new treatments. So, when a common, inexpensive and easy-to-administer drug recently appeared on the radar as a possible MS treatment, it wasn’t surprising that dozens of social media folks jumped to relay word of it. Their…
June 5, 2017 Columns by Ed Tobias MS News That Caught My Eye: An Acne Drug, a High-Cost Gel, Good News About Lemtrada, and Getting Off MS Drugs In case you missed them, here are some news stories that appeared in MS News Today that caught my eye over the past week. Acne Therapy Reduces Rate of Multiple Sclerosis Progression, Canadian Study Reports At first glance, the headlines about this drug announced what seemed to be…
June 2, 2017 News by Alice Melão, MSc Acne Therapy Reduces Rate of Multiple Sclerosis Progression, Canadian Study Reports A common acne medicine called minocycline can reduce the rate of multiple sclerosis progression in patients who are at early stages of the disease, according to a Phase 3 clinical trial. The finding was from the MinoCIS trial (NCT00666887) of minocycline, which goes by the brand name Mynocan and other…
October 13, 2015 News by Patricia Silva, PhD Insights into Promising MS Therapies at Late Breaking News Session, ECTRIMS 2015 A session titled “Late Breaking News” was featured at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 7-10, 2015, in Barcelona, Spain. At this session, Prof. Xavier Montalban from the Hospital Vall d’Hebron University in Barcelona presented data on the promising Genentech/Roche…
